2014
The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018)
Lam W, Jiang Z, Guan F, Hu R, Liu SH, Chu E, Cheng YC. The number of intestinal bacteria is not critical for the enhancement of antitumor activity and reduction of intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018). BMC Complementary Medicine And Therapies 2014, 14: 490. PMID: 25510341, PMCID: PMC4302098, DOI: 10.1186/1472-6882-14-490.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAnti-Bacterial AgentsAntineoplastic Agents, PhytogenicBacteriaCamptothecinColonic NeoplasmsDrugs, Chinese HerbalFemaleGranulocyte Colony-Stimulating FactorHumansIntestinal MucosaIntestinesIrinotecanMiceNeutrophil InfiltrationPhytotherapyReceptors, G-Protein-CoupledRNA, MessengerTumor Necrosis Factor-alphaWeight LossConceptsBody weight lossAntibiotic treatmentCPT-11Tumor-bearing miceIntestinal bacteriaIntestinal toxicityStem cell markersAntitumor activityAnimal body weight lossCPT-11-treated miceCell markersMRNA expressionTNF-alpha mRNA expressionWeight lossAntibiotic treatment groupCPT-11 treatmentCytokines G-CSFProgenitor/stem cell markersLactobacillus/EnterococcusIntestinal damageInflammatory processIntestinal bacterial profilesTreatment groupsPCNA stainingTumor allografts
2007
Intracellular Metabolism and Persistence of the Anti-Human Immunodeficiency Virus Activity of 2′,3′-Didehydro-3′-Deoxy-4′-Ethynylthymidine, a Novel Thymidine Analog
Paintsil E, Dutschman GE, Hu R, Grill SP, Lam W, Baba M, Tanaka H, Cheng YC. Intracellular Metabolism and Persistence of the Anti-Human Immunodeficiency Virus Activity of 2′,3′-Didehydro-3′-Deoxy-4′-Ethynylthymidine, a Novel Thymidine Analog. Antimicrobial Agents And Chemotherapy 2007, 51: 3870-3879. PMID: 17724147, PMCID: PMC2151449, DOI: 10.1128/aac.00692-07.Peer-Reviewed Original ResearchConceptsAnti-human immunodeficiency virus (HIV) activityAnti-HIV activityDrug-resistant virusesD4TNovel thymidine analogVirus activityPotent anti-human immunodeficiency virus activityMultidrug-resistant HIVCurrent antiretroviral therapyDrug removalPatient compliance issuesIntracellular metabolismThymidine analogueLong-term toxicityPromising antiviral candidateNovel antiretroviral compoundsDose-dependent accumulationAntiretroviral therapyMonophosphate metaboliteFrequent dosingAntiretroviral compoundsT metabolitesTherapeutic benefitHIV activityAntiviral candidatesComparison of the Phosphorylation of 4′-Ethynyl 2′,3′-Dihydro-3′-Deoxythymidine with That of Other Anti-Human Immunodeficiency Virus Thymidine Analogs
Hsu CH, Hu R, Dutschman GE, Yang G, Krishnan P, Tanaka H, Baba M, Cheng YC. Comparison of the Phosphorylation of 4′-Ethynyl 2′,3′-Dihydro-3′-Deoxythymidine with That of Other Anti-Human Immunodeficiency Virus Thymidine Analogs. Antimicrobial Agents And Chemotherapy 2007, 51: 1687-1693. PMID: 17353236, PMCID: PMC1855562, DOI: 10.1128/aac.01432-06.Peer-Reviewed Original ResearchConceptsD4TAnti-human immunodeficiency virus (HIV) activityStepwise phosphorylationTMP kinaseMultidrug-resistant HIVActive triphosphate metaboliteT-lymphoid cell linesThymidine analogueNucleoside diphosphate kinaseHuman thymidine kinase 1Antiretroviral agentsAntiretroviral activityRate-limiting enzymeThymidine kinase 1Crude cellular extractsVirus activityDiphosphate kinaseTriphosphate metaboliteCreatine kinaseKinase 1Cellular extractsKinasePhosphorylation efficiencyPhosphorylationPyruvate kinase